Page 7 - Aadi Bioscience News Today

/PRNewswire/ -- The "Global Oncology Partnering 2016-2023: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.coms offering....

/PRNewswire/ -- The "PEComa - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.coms offering. This report delivers an in-depth...

Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) Chairman Neil Desai sold 17,315 shares of the company’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $8.11, for a total value of $140,424.65. Following the transaction, the chairman now directly owns 1,796,803 shares in the company, valued at […]

Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) Chairman Neil Desai sold 4,982 shares of the stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $7.92, for a total value of $39,457.44. Following the transaction, the chairman now owns 1,826,561 shares of the company’s stock, valued at $14,466,363.12. […]

Corporate Presentation June 2023 Forward-Looking Statements ... | June 6, 2023

Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 1,290,000 shares, an increase of 17.3% from the April 30th total of 1,100,000 shares. Currently, 7.7% of the company’s shares are short sold. Based on an average […]

Opaleye Management Inc. acquired a new position in shares of Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 252,046 shares of the company’s stock, valued at approximately $3,234,000. Aadi Bioscience accounts for approximately […]

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision...

Aadi Bioscience (NASDAQ:AADI – Get Rating) had its price target lowered by LADENBURG THALM/SH SH from $47.00 to $33.00 in a research report sent to investors on Thursday morning, The Fly reports. Separately, HC Wainwright reduced their price objective on shares of Aadi Bioscience from $48.00 to $45.00 and set a buy rating for the […]

Operator: Good day and welcome to the Aadi Bioscience First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.